NCT01127295 2026-04-14
PHACS
Institut Claudius Regaud
Phase 4 Completed
Clinical Trials
60 trialsNCT01553903 2026-04-14
OXYTAM
Institut Claudius Regaud
Phase 4 Completed
NCT01612871 2026-04-14
MIRHO
Institut Claudius Regaud
Phase 4 Completed
NCT00893061 2026-03-17
MNEMOSYNE
Centre Oscar Lambret
Phase 3 Completed
NCT02767661 2026-02-27
MECCA
Sun Yat-sen University
Phase 3 Completed
NCT03079011 2025-11-18
PADA-1
UNICANCER
Phase 3 Completed
NCT04300790 2025-07-29
METALLICA
MedSIR
Phase 2 Completed
NCT05635357 2025-07-28
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole
Brigham and Women's Hospital
Completed
NCT00253422 2025-06-04
SoFEA
Institute of Cancer Research, United Kingdom
Phase 3 Completed
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03219476 2025-04-29
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT00265759 2025-04-23
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT01870505 2024-12-09
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03355157 2024-10-01
PADMA
GBG Forschungs GmbH
Phase 4 Completed
NCT02028507 2024-09-25
PEARL
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT02188745 2024-07-17
POLLY
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT02676986 2024-07-05
ARB
Queen Mary University of London
Phase 2 Completed
NCT01594216 2024-06-12
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT04129216 2024-05-07
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Johns Hopkins University
Phase 2 Completed
NCT02648477 2024-03-19
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT01814397 2024-02-07
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
University of Michigan Rogel Cancer Center
Completed
NCT00719966 2024-01-02
Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer
Mayo Clinic
Completed
NCT04465097 2023-10-17
NeoTEE
First Affiliated Hospital, Sun Yat-Sen University
Phase 2 Completed
NCT02028364 2023-08-24
PEARL
Jules Bordet Institute
Phase 2 Completed
NCT03555877 2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2 Completed
NCT02666105 2023-05-31
Exemestane in Post-Menopausal Women With NSCLC
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00432172 2023-04-03
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT00128843 2023-03-06
Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT02440230 2022-12-30
SEAT
Shanghai Jiao Tong University School of Medicine
Phase 2 Completed
NCT03948568 2022-09-30
REaCT-RETT
Ottawa Hospital Research Institute
Phase 4 Completed
NCT02871791 2022-08-29
Palbociclib With Everolimus + Exemestane In BC
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01989780 2022-08-04
BOOSTER
Japan Breast Cancer Research Group
Phase 2 Completed
NCT01831076 2022-03-03
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
University of Colorado, Denver
Phase 2 Completed
NCT04659551 2020-12-09
GIADA
Istituto Oncologico Veneto IRCCS
Phase 2 Completed
NCT02511639 2020-12-03
MAIN-A
Istituto Oncologico Veneto IRCCS
Phase 3 Completed
NCT00810797 2020-10-19
Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT01963481 2020-03-17
Exemestane and Cyclophosphamide for Metastatic Breast Cancer
NYU Langone Health
Phase 2 Completed
NCT02291913 2020-02-17
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01720602 2020-01-07
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
University of Washington
Phase NA Completed
NCT00240071 2019-10-30
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.
University of Alabama at Birmingham
Phase 2 Completed
NCT01153672 2019-09-06
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
University of Washington
Phase NA Completed
NCT01664754 2019-05-07
Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT01385280 2018-10-17
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
University of Arizona
Phase NA Completed
NCT01638247 2018-09-19
MALE
GBG Forschungs GmbH
Phase 3 Completed
NCT00201864 2018-07-26
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02549430 2017-08-01
TREnd
Fondazione Sandro Pitigliani
Phase 2 Completed
NCT00941330 2017-04-10
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Emory University
Phase 2 Completed
NCT01654185 2017-03-14
Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer
Fudan University
Phase 2 Completed